Bevacizumab (Genentech Inc., South San Francisco, CA, USA), a humanized monoclonal antibody that inhibits all VEGF isoforms, has shown promising results against CNVs that were secondary to AMD.[11‐14] Gomi et al.,[15] reported that intravitreal bevacizumab (IVB) was effective in reducing the fluid from PCV but not for diminishing choroidal vascular changes. Here, VEGFA is linked to age-related macular degeneration.